UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

Quality of life of patients with hematological malignancies and factors affecting health state utility values

Supportive care in cancer, 2022-06, Vol.30 (6), p.5319-5327

2022

Volltextzugriff (PDF)

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

Blood advances, 2022-01, Vol.6 (1), p.238-247

2022

Volltextzugriff (PDF)

Future prospect of RNA interference for cancer therapies

Current drug targets, 2010-03, Vol.11 (3), p.345

2010

Volltextzugriff (PDF)

Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma

Cancer research (Chicago, Ill.), 2014-12, Vol.74 (24), p.7418-7429

2014

Volltextzugriff (PDF)

Paroxysmal nocturnal hemoglobinuria complicated with essential thrombocythemia harboring concomitant PIGA, CALR, and ASXL1 mutations

Annals of hematology, 2021-08, Vol.100 (8), p.2113-2115

2021

Volltextzugriff (PDF)

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Blood, 2005-12, Vol.106 (12), p.3948-3954

2005

Volltextzugriff (PDF)

NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia

International journal of hematology, 2022-08, Vol.116 (2), p.199-214

2022

Volltextzugriff (PDF)

Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective study

Cancer medicine (Malden, MA), 2023-02, Vol.12 (3), p.3134-3144

2023

Volltextzugriff (PDF)

Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era

International journal of hematology, 2017-05, Vol.105 (5), p.658-667

2017

Volltextzugriff (PDF)

Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations

Haematologica (Roma), 2016-09, Vol.101 (9), p.1074

2016

Volltextzugriff (PDF)

Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study

International journal of hematology, 2019-07, Vol.110 (1), p.77-85

2019

Volltextzugriff (PDF)

Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma

Diagnostics (Basel), 2021-09, Vol.11 (9), p.1724

2021

Volltextzugriff (PDF)

Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma

Hematological oncology, 2021-08, Vol.39 (3), p.349-357

2021

Volltextzugriff (PDF)

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity

Blood, 2007-01, Vol.109 (1), p.306-314

2007

Volltextzugriff (PDF)

Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR , JAK2V617F, JAK2Ex12del , and MPLW515L/K mutations

Leukemia research, 2016-01, Vol.40, p.68-76

2016

Volltextzugriff (PDF)

Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer

Molecular cancer therapeutics, 2008-09, Vol.7 (9), p.2904-2912

2008

Volltextzugriff (PDF)

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

Leukemia research reports, 2023-01, Vol.20, p.100395-100395, Article 100395

2023

Volltextzugriff (PDF)

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin

International journal of hematology, 2008-06, Vol.87 (5), p.507-515

2008

Volltextzugriff (PDF)

Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy

Cancer medicine (Malden, MA), 2018-03, Vol.7 (3), p.655-664

2018

Volltextzugriff (PDF)

A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro

Cancer letters, 2010-08, Vol.294 (2), p.245-253

2010

Volltextzugriff (PDF)

Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka

International journal of hematology, 2010-11, Vol.92 (4), p.579-586

2010

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(93)

Publikationsform

Artikel
(98)
Berichte
(4)

Sprache

Englisch
(99)
Japanisch
(25)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Quality of life of patients with hematological malignancies and factors affecting health state utility values

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia

Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia

Future prospect of RNA interference for cancer therapies

Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma

Paroxysmal nocturnal hemoglobinuria complicated with essential thrombocythemia harboring concomitant PIGA, CALR, and ASXL1 mutations

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia

Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study

Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia

Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa‐associated lymphoid tissue lymphoma: A retrospective study

Detection of chromosomal abnormalities by G-banding and prognostic impact in follicular lymphoma in the rituximab era

Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations

Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study

Combination of Bone Marrow Biopsy and Flow Cytometric Analysis: The Prognostically Relevant Central Approach for Detecting Bone Marrow Invasion in Diffuse Large B-Cell Lymphoma

Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma

P654: ALLELIC POLYMORPHISMS OF KIRS AND HLAS PREDICT FAVORABLE ACHIEVEMENT OF TREATMENT‐FREE REMISSION IN CML: RESULTS FROM THE POKSTIC TRIAL, MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity

Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR , JAK2V617F, JAK2Ex12del , and MPLW515L/K mutations

Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer

Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin

Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy

A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro

Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka

Suchergebnisse filtern